Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026
Goldenwell Biotech, Inc. (GWLL) files with the SEC under industry code 2000, Food and Kindred Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $36,876. As of Jun 30, 2026 it held $11,143 in cash and investments and $0 in total debt.
Revenue
$0
Net income
$-36,876
-21.7% vs year-ago quarter
Operating cash flow
$-47,271
-179.6% vs year-ago quarter
Free cash flow
—
EPS
$0.00
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
99.00M
+0.0% vs year-ago quarter
Net cash
$11,143
Q2 FY2026
Operating margin
-196772.7%
TTM
Company profile
- Industry
- Food and Kindred Products (SIC 2000)
- Listed as
- GWLL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Solon, OH
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1800373
Other Food and Kindred Products companies
- Mondelez International, Inc. MDLZ
- Conagra Brands Inc. CAG
- CAMPBELL'S Co CPB
- Nomad Foods Ltd NOMD
- Flowers Foods Inc FLO
- Bellring Brands, Inc. BRBR
- Simply Good Foods Co SMPL
- Vital Farms, Inc. VITL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $55 | — | $0 |
| Operating income | -$34,776 | -$31,335 | -$22,895 | -$25,795 | -$28,200 |
| Net income | -$36,876 | -$17,606 | -$199,740 | -$27,895 | -$30,300 |
| Diluted EPS | $0.00 | $0.00 | $0.00 | -$0.00 | -$0.00 |
| Operating cash flow | -$47,271 | -$13,361 | -$18,848 | -$30,885 | $59,380 |
| Total assets | $28,978 | $18,754 | $36,120 | $233,760 | $267,315 |
| Total liabilities | $427,173 | $380,073 | $379,833 | $377,733 | $383,393 |
| Stockholders' equity | -$398,195 | -$361,319 | -$343,713 | -$143,974 | -$116,079 |
| Cash and investments | $11,143 | $13,414 | $26,775 | $45,622 | $76,507 |
| Total debt | $0 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 29, 2026 | Sep 27, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jul 1, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Jul 1, 2026 | Dec 31, 2025 |
| 10-Q/A | Amended quarterly report | Jun 29, 2026 | Sep 30, 2025 |
All 85 Goldenwell Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.